Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 153Carcinoma, Non-Small-Cell Lung 34Skin Neoplasms 30Colorectal Neoplasms 29Breast Neoplasms 26Lung Neoplasms 25Carcinoma, Renal Cell 21Carcinoma, Basal Cell 21Ovarian Neoplasms 20Neoplasms 20Squamous Cell Carcinoma of Head and Neck 19Sarcoma 19Carcinoma, Merkel Cell 19Prostatic Neoplasms 17Pancreatic Neoplasms 16Neoplasm Metastasis 15Head and Neck Neoplasms 15Stomach Neoplasms 13Thyroid Neoplasms 12Uterine Cervical Neoplasms 11Urinary Bladder Neoplasms 11Carcinoma, Hepatocellular 11Lymphoma, T-Cell, Cutaneous 10Esophageal Neoplasms 10Carcinoma, Transitional Cell 10Uveal Melanoma 8Triple Negative Breast Neoplasms 8Mycosis Fungoides 8Gastrointestinal Neoplasms 8Colonic Neoplasms 8

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Dermatologic × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡